Drug Combination Details

General Information of the Combination (ID: C42410)
Name Fisetin   NP Info  + Cyclophosphamide   Drug Info 
Structure +
Disease
Lung cancer [ICD-11: 2C25]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation		 Down-regulation Expression PECAM1  Molecule Info 
Pathway MAP
                    In-vitro Model EA.hy 926 CVCL_3901 Healthy Homo sapiens
3LL CVCL_5653 Malignant tumors Mus musculus
NIH 3T3 CVCL_0594 Healthy Mus musculus
                    In-vivo Model Aliquots of cells (0.1 ml, 3 * 106 cells) were mixed with 0.2 ml of phenol red-free Matrigel and injected into the right flank of mice.
                    Experimental
                    Result(s)		 Fisetin not only displays in vitro and in vivo antiangiogenic properties, but also can markedly improve the in vivo antitumour effect of CPA.
References
Reference 1 Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemother Pharmacol. 2011 Aug;68(2):445-55.
 Download Picture         KEGG Link